SCHEMBL13638309

SCHEMBL13638309

C=C1CC(Nc2nccc(-c3cc4cc(C)ccc4s3)n2)CC(C)(C)N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.38
CDK4 P11802 7/20 0.35
CDK2 P24941 6/20 0.35
CDK1 P06493 5/20 0.35
CCNB1 P14635 5/20 0.35
CCNA2 P20248 5/20 0.35
CCND1 P24385 5/20 0.35
CCNA1 P78396 4/20 0.35
IKBKB O14920 6/20 0.32
CHUK O15111 4/20 0.32
IKBKG Q9Y6K9 4/20 0.32
HDAC8 Q9BY41 3/20 0.32
EIF2AK2 P19525 2/20 0.31
CCND3 P30281 2/20 0.31
CDK6 Q00534 2/20 0.31
CCNE1 P24864 1/20 0.31
GSK3B P49841 1/20 0.31
CCNT1 O60563 1/20 0.30
CDK7 P50613 1/20 0.30
CDK9 P50750 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3471385 0.86 KCNH2 (0.50) KCNH2CDK4CDK2CDK1CCNB1
SCHEMBL13638307 0.85 KCNH2 (0.38) KCNH2CDK4CDK2CDK1CCNB1
SCHEMBL13638581 0.84 EIF2AK2 (0.40) KCNH2CDK4IKBKBCHUKIKBKG
SCHEMBL14612785 0.81 IKBKB (0.37) KCNH2CDK4CDK2CDK1CCNB1
SCHEMBL13638454 0.81 CDK4 (0.36) CDK4CDK2CDK1CCNB1CCNA2
SCHEMBL13638308 0.80 KCNH2 (0.34) KCNH2IKBKBEIF2AK2
SCHEMBL13638676 0.80 MKNK1 (0.36) KCNH2CDK4CDK2CDK1CCNB1
SCHEMBL13638286 0.79 ROCK2 (0.35) KCNH2CDK4CDK2CDK1CCNB1
SCHEMBL13638420 0.79 KDM4E (0.38) CDK4CDK2CDK1CCNB1CCNA2
SCHEMBL13638524 0.79 KCNH2 (0.33) KCNH2EIF2AK2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK KCNH2 3073/4885CDK4 681/4885CDK2 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.